Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 1
2002 4
2004 1
2005 2
2006 2
2007 2
2008 1
2009 2
2010 3
2011 2
2012 2
2014 2
2015 1
2019 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Keratinocyte growth factor ameliorates mycophenolate mofetil-induced intestinal barrier disruption in mice.
Song Y, Hu W, Xiao Y, Li Y, Wang X, He W, Hou J, Liu Y, Liang G, Huang C. Song Y, et al. Mol Immunol. 2020 Aug;124:61-69. doi: 10.1016/j.molimm.2020.04.012. Epub 2020 Jun 10. Mol Immunol. 2020. PMID: 32534355 Free article.
METHODS: Thirty adult male C57BL/6 mice were assigned to one of the following groups: the MMF group, the MMF + KGF group, and the control group (n = 10 in each group). Animals in the MMF group received MMF (500 mg/kg) by gavage once daily for 15 consecutive days; an …
METHODS: Thirty adult male C57BL/6 mice were assigned to one of the following groups: the MMF group, the MMF + KGF group, and the control gr …
Bioavailability of a new generic formulation of mycophenolate mofetil MMF 500 versus CellCept in healthy adult volunteers.
Masri MA, Rizk S, Attia ML, Barbouch H, Rost M. Masri MA, et al. Transplant Proc. 2007 May;39(4):1233-6. doi: 10.1016/j.transproceed.2007.03.055. Transplant Proc. 2007. PMID: 17524942 Clinical Trial.
We compared the pharmacokinetic profile of a new MMF generic formulation (MMF 500 batch number: 06T3001; Medis Tunis) with those of Cellcept, (batch number: M1427; Hoffmann La Roche, Switzerland) in healthy volunteers. ...The 90% confidence intervals (LSM) of Cmax, …
We compared the pharmacokinetic profile of a new MMF generic formulation (MMF 500 batch number: 06T3001; Medis Tunis) with tho …
Mycophenolate mofetil 500-mg tablet under fasting conditions: single-dose, randomized-sequence, open-label, four-way replicate crossover, bioequivalence study in healthy subjects.
Almeida S, Filipe A, Neves R, Spínola AC, Tanguay M, Ortuño J, Farré A, Torns A. Almeida S, et al. Clin Ther. 2010 Mar;32(3):556-74. doi: 10.1016/j.clinthera.2010.03.008. Clin Ther. 2010. PMID: 20399993 Clinical Trial.
OBJECTIVE: The aim of this study was to assess the bioequivalence of a generic (test) and branded (reference) formulation of MMF 500 mg and MPA. METHODS: This single-center, single-dose, randomized, open-label, 4-way crossover study was conducted at Anapharm's Clini …
OBJECTIVE: The aim of this study was to assess the bioequivalence of a generic (test) and branded (reference) formulation of MMF 5
Refractory Anemia in a Kidney Transplant Recipient.
Duarte I, Gameiro J, Outerelo C, Nogueira E, Lopes JA. Duarte I, et al. Int J Organ Transplant Med. 2019;10(4):188-190. Int J Organ Transplant Med. 2019. PMID: 33312464 Free PMC article.
Induction immunosuppression therapy consisted of thymoglobulin, tacrolimus (TAC) and methylprednisolone; the maintenance therapy included mycophenolate (MMF) 500 + 500 mg, TAC 4 + 4 mg and prednisolone (PD) 5 mg. One year after KT, he progressively developed dyspnea …
Induction immunosuppression therapy consisted of thymoglobulin, tacrolimus (TAC) and methylprednisolone; the maintenance therapy included my …
Use of mycophenolate mofetil in inflammatory bowel disease.
Tan T, Lawrance IC. Tan T, et al. World J Gastroenterol. 2009 Apr 7;15(13):1594-9. doi: 10.3748/wjg.15.1594. World J Gastroenterol. 2009. PMID: 19340901 Free PMC article.
METHODS: Crohn's disease (CD) or ulcerative colitis/IBD unclassified (UC/IBDU) patients intolerant or refractory to conventional medical therapy received MMF (500-2000 mg bid). Clinical response was assessed by the Harvey Bradshaw index (HBI) or colitis activity ind …
METHODS: Crohn's disease (CD) or ulcerative colitis/IBD unclassified (UC/IBDU) patients intolerant or refractory to conventional medical the …
Single-dose, two-way crossover, bioequivalence study of Mycophenolate mofetil 500 mg tablet under fasting conditions in healthy male subjects.
Patel S, Chauhan V, Mandal J, Shah S, Patel K, Saptarshi D, Maheshwari K, Jha PK, Kale P, Patel K, Mathew P. Patel S, et al. Clin Ther. 2011 Mar;33(3):378-90. doi: 10.1016/j.clinthera.2011.04.003. Clin Ther. 2011. PMID: 21600390 Clinical Trial.
OBJECTIVES: The aims of the 2 studies reported were to assess the dissolution and bioavailability of a generic (test) and branded (reference) formulation of MMF 500 mg. METHODS: An in vitro analytical dissolution profile test was conducted comparing 500 mg MMF test …
OBJECTIVES: The aims of the 2 studies reported were to assess the dissolution and bioavailability of a generic (test) and branded (reference …
Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers.
Kees MG, Steinke T, Moritz S, Rupprecht K, Paulus EM, Kees F, Bucher M, Faerber L. Kees MG, et al. J Clin Pharmacol. 2012 Aug;52(8):1265-72. doi: 10.1177/0091270011412968. Epub 2011 Sep 8. J Clin Pharmacol. 2012. PMID: 21903891
The plasma concentrations of mycophenolic acid (MPA) and of the inactive metabolite mycophenolic acid glucuronide (MPA-G) were measured by high-performance liquid chromatography (HPLC). In addition, dissolution of MMF 500 mg or EC-MPS 360 mg tablets was determined u …
The plasma concentrations of mycophenolic acid (MPA) and of the inactive metabolite mycophenolic acid glucuronide (MPA-G) were measured by h …
Comparison of the exposure of mycophenolate mofetil and enteric-coated mycophenolate sodium in recipients of kidney-pancreas transplantation.
Belliere J, Esposito L, Gandia P, Duffas JP, Sallusto F, Cardeau-Desangles I, Del Bello A, Rostaing L, Kamar N. Belliere J, et al. Ann Transplant. 2014 Feb 10;19:76-81. doi: 10.12659/AOT.889691. Ann Transplant. 2014. PMID: 24509827 Free article.
MPA AUC(0-12) values were obtained before and after the switch, ie, under MMF (500 mg b.i.d.) at 169 (51-1522) days post-transplantation and EC-MPS (360 mg b.i.d.) at 102 (26-355) days after the switch. ...
MPA AUC(0-12) values were obtained before and after the switch, ie, under MMF (500 mg b.i.d.) at 169 (51-1522) days post-trans …
Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease.
Skelly MM, Logan RF, Jenkins D, Mahida YR, Hawkey CJ. Skelly MM, et al. Inflamm Bowel Dis. 2002 Mar;8(2):93-7. doi: 10.1097/00054725-200203000-00004. Inflamm Bowel Dis. 2002. PMID: 11854606 Clinical Trial.
Twelve patients [seven with Crohn's disease (CD); seven women; mean age 40 years, range 14-76 years] were treated with MMF 500 mg b.i.d. for a mean of 12.5 weeks. Intolerance was defined as the development of side effects that resolved on discontinuing MMF. ...
Twelve patients [seven with Crohn's disease (CD); seven women; mean age 40 years, range 14-76 years] were treated with MMF 500
Case series assessing the safety of mycophenolate as part of multidrug rescue treatment regimens.
Press N, Kimel G, Harris M, Yip B, Craib KJ, Montaner JS. Press N, et al. HIV Clin Trials. 2002 Jan-Feb;3(1):17-20. doi: 10.1310/B6T0-N98J-1J3M-EQPK. HIV Clin Trials. 2002. PMID: 11819181 Clinical Trial.
PURPOSE: To assess the safety of MMF as adjunctive therapy for HIV infection. METHOD: Eighteen HIV-positive outpatients, given MMF (500 mg po bid) on a compassionate basis as part of their salvage therapy, were monitored for adverse effects. ...Three patients exhibi …
PURPOSE: To assess the safety of MMF as adjunctive therapy for HIV infection. METHOD: Eighteen HIV-positive outpatients, given MMF ( …
26 results